{
  "content": "Open in Viewer\nCentral Illustration. Patient Outcomes by Amiodarone Use at Randomization\nEvent rates and hazard ratios (HRs) comparing apixaban to warfarin by amiodarone use at randomization. CV= cardiovascular; SE= systemic embolism.",
  "source": "https://www.jacc.org/doi/10.1016/j.jacc.2014.07.967",
  "chunk_id": "8628514f-43d5-41bd-95bf-1f7600983bf2",
  "similarity_score": 0.308017373085022,
  "query": "atrial fibrillation mortality outcomes cardiovascular events stroke prevention amiodarone beta-blockers hazard ratio",
  "rank": 34,
  "title": "Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial",
  "authors": "Greg Flaker, Renato D. Lopes, Elaine Hylek, Daniel M. Wojdyla, Laine Thomas, Sana M. Al-Khatib, Renee M. Sullivan, Stefan H. Hohnloser, David Garcia, Michael Hanna, John Amerena, Veli-Pekka Harjola, Paul Dorian, Alvaro Avezum, Matyas Keltai, Lars Wallentin, Christopher B. Granger",
  "year": "2014",
  "journal": "JACC",
  "reference": "Flaker, G., Lopes, R. D., Hylek, E., Wojdyla, D. M., Thomas, L., Al-Khatib, S. M., Sullivan, R. M., Hohnloser, S. H., Garcia, D., Hanna, M., Amerena, J., Harjola, V.-P., Dorian, P., Avezum, A., Keltai, M., Wallentin, L., & Granger, C. B. (2014). Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: Insights from the ARISTOTLE trial. JACC, 64(15), 556-575.",
  "doi": "Not available",
  "chunk_index": 61,
  "total_chunks": 111,
  "retrieved_at": "2025-07-24T21:57:59.084694"
}